Let's talk

Dr Jonathan Pearson-Stuttard

Partner & Head of Health Analytics

I am Head of Health Analytics at LCP. As a Public Health Physician and Epidemiologist, I am also Chair of the Health Inequalities Programme Board at Northumbria Healthcare NHS Foundation Trust, Chair of the Royal Society for Public Health and Honorary Clinical Senior Lecturer at Imperial College London.

At LCP, I lead a multidisciplinary analytics team developing innovative analytics and technology approaches that cut through the noise of complex datasets and put actionable insights into the hands of decision-makers across health and life sciences. Our areas of work include value-based care frameworks, quantifying co- and multi-morbidity health needs and service costs, and identifying patient groups with the most unmet need in order to prioritize resource allocation, will help to shift health systems from importers of illness to exporters of health.

I was Editor-in-Chief of the Chief Medical Officer's 2018 Report 'Health 2040 – Better Health Within Reach’, which recommended the development of a composite Health Index. This Index was published by the UK's Office for National Statistics in 2020, and I remain closely involved. I co-authored the book, ‘Whose health is it, anyway?’ with Dame Sally Davies, which repositions health as the greatest untapped opportunity for prosperity, happiness and fairness in the 21st century. Through my work chairing Northumbria’s Health Inequalities Programme Board, I put this approach into action.

I trained at the University of Oxford, and have been awarded multiple competitive clinical-academic research positions from the NIHR and the Wellcome Trust at Imperial College London. My research has three main streams spanning non-communicable disease epidemiology:

  • First, using big data and simulation modeling of health, economic and inequality outcomes to inform public health policy.
  • Second, investigating the increasing diversification of morbidity and mortality in patients with diabetes and other chronic diseases.
  • Third, estimating the increasing heterogeneity and inequalities in life expectancy trends across the UK and the potential indirect impacts of the Covid-19 impact on these trends.

LCP are a professional organization, which understands the clients' needs and demonstrates the depth and creativity of its experience in the solutions it provides.

LCP Client

Featured insights

Breaking Waves

Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices

Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.

Read now

Yosemite National Park Waterfall

Reimagining patient support in the era of MFN: A strategic imperative for manufacturers

Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.

Read now

Rocky Mountain River

Achieving equitable representation in clinical trials

Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.

Read now

Redwood Forest

Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?

In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.

Listen now